Aberrant DNA methylation of T-cell leukemia, homeobox 3 modulates cisplatin sensitivity in bladder cancer

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Cisplatin resistance is a significant challenge in bladder cancer treatment.
• Identifying biomarkers for cisplatin resistance is crucial for improving patient outcomes.
• Epigenetic modifications, such as DNA methylation, play a role in cancer progression and drug resistance.

Purpose of the Study:

• To investigate the role of the TLX3 gene in cisplatin resistance in bladder cancer.
• To identify TLX3 methylation as a potential biomarker for predicting cisplatin sensitivity.
• To explore therapeutic strategies targeting TLX3 methylation in bladder cancer.

Main Methods:

• Utilized cell lines with varying cisplatin sensitivity to examine TLX3 methylation status.
• Employed TLX3-specific shRNA to suppress TLX3 expression and assess its impact on cisplatin resistance.
• Overexpressed TLX3 in resistant cells to evaluate changes in cisplatin sensitivity.
• Analyzed TLX3 methylation patterns in clinical bladder cancer samples using the COBRA assay.
• Correlated TLX3 methylation status with cisplatin sensitivity using the SDI test.

Main Results:

• TLX3 was found to be unmethylated in cisplatin-sensitive cells and methylated in resistant cells.
• Suppression of TLX3 expression increased cisplatin resistance, while TLX3 overexpression enhanced sensitivity.
• The COBRA assay revealed TLX3 methylation in 21% of 110 clinical bladder cancer samples.
• A significant correlation was observed between TLX3 methylation and cisplatin sensitivity in clinical samples.

Conclusions:

• TLX3 methylation serves as a potential epigenetic biomarker for cisplatin resistance in bladder cancer.
• The methylation status of TLX3 is closely associated with cisplatin sensitivity.
• Targeting TLX3 methylation could offer novel therapeutic approaches to overcome cisplatin resistance in bladder cancer.